85 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp01214 | ATP-binding cassette sub-family C member 3 | MDALCGSGELGSKFWDSNLSVHTENPDLTPCFQNSLLAWVPCIYLWVALPCYLLYLRHHCRGYIILSHLSKLKMVLGVLLWCVSWADLFYSFHGLVHGRAPAPVFFVTPLVVGVTMLLATLLIQYERLQGVQSSGVLIIFWFLCVVCAIVPFRSKILLAKAEGEISDPFRFTTFYIHFALVLSALILACFREKPPFFSAKNVDPNPYPETSAGFLSRLFFWWFTKMAIYGYRHPLEEKDLWSLKEEDRSQMVVQQLLEAWRKQEKQTARHKASAAPGKNASGEDEVLLGARPRPRKPSFLKALLATFGSSFLISACFKLIQDLLSFINPQLLSILIRFISNPMAPSWWGFLVAGLMFLCSMMQSLILQHYYHYIFVTGVKFRTGIMGVIYRKALVITNSVKRASTVGEIVNLMSVDAQRFMDLAPFLNLLWSAPLQIILAIYFLWQNLGPSVLAGVAFMVLLIPLNGAVAVKMRAFQVKQMKLKDSRIKLMSEILNGIKVLKLYAWEPSFLKQVEGIRQGELQLLRTAAYLHTTTTFTWMCSPFLVTLITLWVYVYVDPNNVLDAEKAFVSVSLFNILRLPLnMLPQLISNLTQASVSLKRIQQFLSQEELDPQSVERKTISPGYAITIHSGTFTWAQDLPPTLHSLDIQVPKGALVAVVGPVGCGKSSLVSALLGEMEKLEGKVHMKGSVAYVPQQAWIQNCTLQENVLFGKALNPKRYQQTLEACALLADLEMLPGGDQTEIGEKGINLSGGQRQRVSLARAVYSDADIFLLDDPLSAVDSHVAKHIFDHVIGPEGVLAGKTRVLVTHGISFLPQTDFIIVLADGQVSEMGPYPALLQRNGSFANFLCNYAPDEDQGHLEDSWTALEGAEDKEALLIEDTLSNHTDLTDNDPVTYVVQKQFMRQLSALSSDGEGQGRPVPRRHLGPSEKVQVTEAKADGALTQEEKAAIGTVELSVFWDYAKAVGLCTTLAICLLYVGQSAAAIGANVWLSAWTNDAMADSRQNNTSLRLGVYAALGILQGFLVMLAAMAMAAGGIQAARVLHQALLHNKIRSPQSFFDTTPSGRILNCFSKDIYVVDEVLAPVILMLLNSFFNAISTLVVIMASTPLFTVVILPLAVLYTLVQRFYAATSRQLKRLESVSRSPIYSHFSETVTGASVIRAYNRSRDFEIISDTKVDANQRSCYPYIISNRWLSIGVEFVGNCVVLFAALFAVIGRSSLNPGLVGLSVSYSLQVTFALNWMIRMMSDLESNIVAVERVKEYSKTETEAPWVVEGSRPPEGWPPRGEVEFRNYSVRYRPGLDLVLRDLSLHVHGGEKVGIVGRTGAGKSSMTLCLFRILEAAKGEIRIDGLNVADIGLHDLRSQLTIIPQDPILFSGTLRMNLDPFGSYSEEDIWWALELSHLHTFVSSQPAGLDFQCSEGGENLSVGQRQLVCLARALLRKSRILVLDEATAAIDLETDNLIQATIRTQFDTCTVLTIAHRLNTIMDYTRVLVLDKGVVAEFDSPANLIAARGIFYGMARDAGLA | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 ± SD : >250 μM |
| dbacp01218 | ATP-binding cassette sub-family C member 5 | MKDIDIGKEYIIPSPGYRSVRERTSTSGTHRDREDSKFRRTRPLECQDALETAARAEGLSLDASMHSQLRILDEEHPKGKYHHGLSALKPIRTTSKHQHPVDNAGLFSCMTFSWLSSLARVAHKKGELSMEDVWSLSKHESSDVNCRRLERLWQEELNEVGPDAASLRRVVWIFCRTRLILSIVCLMITQLAGFSGPAFMVKHLLEYTQATESNLQYSLLLVLGLLLTEIVRSWSLALTWALNYRTGVRLRGAILTMAFKKILKLKNIKEKSLGELINICSNDGQRMFEAAAVGSLLAGGPVVAILGMIYNVIILGPTGFLGSAVFILFYPAMMFASRLTAYFRRKCVAATDERVQKMNEVLTYIKFIKMYAWVKAFSQSVQKIREEERRILEKAGYFQSITVGVAPIVVVIASVVTFSVHMTLGFDLTAAQAFTVVTVFNSMTFALKVTPFSVKSLSEASVAVDRFKSLFLMEEVHMIKNKPASPHIKIEMKNATLAWDSSHSSIQNSPKLTPKMKKDKRASRGKKEKVRQLQRTEHQAVLAEQKGHLLLDSDERPSPEEEEGKHIHLGHLRLQRTLHSIDLEIQEGKLVGICGSVGSGKTSLISAILGQMTLLEGSIAISGTFAYVAQQAWILNATLRDNILFGKEYDEERYNSVLNSCCLRPDLAILPSSDLTEIGERGANLSGGQRQRISLARALYSDRSIYILDDPLSALDAHVGNHIFNSAIRKHLKSKTVLFVTHQLQYLVDCDEVIFMKEGCITERGTHEELMNLNGDYATIFNNLLLGETPPVEINSKKETSGSQKKSQDKGPKTGSVKKEKAVKPEEGQLVQLEEKGQGSVPWSVYGVYIQAAGGPLAFLVIMALFMLNVGSTAFSTWWLSYWIKQGSGNTTVTRGNETSVSDSMKDNPHMQYYASIYALSMAVMLILKAIRGVVFVKGTLRASSRLHDELFRRILRSPMKFFDTTPTGRILNRFSKDMDEVDVRLPFQAEMFIQNVILVFFCVGMIAGVFPWFLVAVGPLVILFSVLHIVSRVLIRELKRLDNITQSPFLSHITSSIQGLATIHAYNKGQEFLHRYQELLDDNQAPFFLFTCAMRWLAVRLDLISIALITTTGLMIVLMHGQIPPAYAGLAISYAVQLTGLFQFTVRLASETEARFTSVERINHYIKTLSLEAPARIKNKAPSPDWPQEGEVTFENAEMRYRENLPLVLKKVSFTIKPKEKIGIVGRTGSGKSSLGMALFRLVELSGGCIKIDGVRISDIGLADLRSKLSIIPQEPVLFSGTVRSNLDPFNQYTEDQIWDALERTHMKECIAQLPLKLESEVMENGDNFSVGERQLLCIARALLRHCKILILDEATAAMDTETDLLIQETIREAFADCTMLTIAHRLHTVLGSDRIMVLAQGQVVEFDTPSVLLSNDSSRFYAMFAAAENKVAVKG | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 ± SD : >250 μM |
| dbacp01258 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10-100 µM |
| dbacp01267 | Aurein 3.1 | GLFDIVKKIAGHIAGSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10-100 µM |
| dbacp01277 | Aurein 3.2 | GLFDIVKKIAGHIASSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01287 | Aurein 3.3 | GLFDIVKKIAGHIVSSI | Southern bell frog, Australia | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01298 | Aurein-1.3 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | CAKI-1 | Renal cancer | IC50 : 5 μM |
| dbacp01317 | Aurein-2.5 | MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE | Green and golden bell frog | Not specified | Not specified | Not found | Renal cancer | Not found |
| dbacp01326 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Not specified | Not specified | Not found | Renal cancer | Not found |
| dbacp01335 | Aurein-2.5 | GLFDIVKKVVGAFGSL | Green and golden bell frog | Cell membrane disintegration | One-dose and five-dose assay | ACHN | Renal cancer | IC50 : 5 μM |
| dbacp01353 | Aurein-2.7 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | RXF 393 | Renal cancer | IC50 : 5 μM |
| dbacp01364 | Aurein-3.1 [Cleaved into: Aurein-3.1.1; Aurein-3.1.2] | GLFDIVKKIAGHIAGSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | 786-0 | Renal cancer | IC50 : 5 μM |
| dbacp01377 | Aurein-3.2 | GLFDIVKKIAGHIASSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | A498 | Renal cancer | IC50 : 5 μM |
| dbacp01389 | Aurein-3.3 [Cleaved into: Aurein-3.3.1] | GLFDIVKKIAGHIVSSI | Southern bell frog | Cell membrane disintegration | One-dose and five-dose assay | SN12C | Renal cancer | IC50 : 5 μM |
| dbacp01412 | Aurein1.2 | GLFDIIKKIAESF | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01421 | Aurein2.5 | GLFDIVKKVVGAFGSL | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01430 | Aurein2.6 | GLFDIAKKVIGVIGSL | Southern bell frog | Cell membrane disruption | Not specified | Renal tumor cell line | Renal cancer | LC50 : 10 µM |
| dbacp01917 | BPP-II | MTLTG | Immunomodulatory bursal-derived Pentapeptide-II | Inducing apoptosis | MTT/MTS assay | Vero | Renal cancer | Not found |
| dbacp01918 | BPP-II | MTLTG | Immunomodulatory bursal-derived Pentapeptide-II | Inducing apoptosis | MTT/MTS assay | MDBK | Renal cancer | Not found |
| dbacp02025 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | 786-0 | Renal cancer | IC50 : 12.2 µg/ml |
| dbacp02026 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | A-498 | Renal cancer | IC50 : 10 µg/ml |
| dbacp02027 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | ACHN | Renal cancer | IC50 : 12 µg/ml |
| dbacp02028 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | CAKI-1 | Renal cancer | IC50 : 14.1 µg/ml |
| dbacp02029 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | RFX393 | Renal cancer | IC50 : 11 µg/ml |
| dbacp02030 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | SN-12C | Renal cancer | IC50 : 11.4 µg/ml |
| dbacp02031 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | TK-10 | Renal cancer | IC50 : 13.1 µg/ml |
| dbacp02032 | Buforin IIb | RAGLQFPVGRLLRRLLRRLLR | Histone H2A | Inducing mitochondria-dependent apoptosis | MTT/MTS assay | UO-31 | Renal cancer | IC50 : 10.6 µg/ml |
| dbacp02271 | Camel | KWKLFKKIGAVLKVL | Ceropin-Melittin hybrid | Cell swelling and rupture of the plasma membrane | MTT/MTS assay | RENCA | Renal cancer | LC50 : 1.3 µM |
| dbacp02312 | Cathelicidin antimicrobial peptide | MKTQRDGHSLGRWSLVLLLLGLVMPLAIIAQVLSYKEAVLRAIDGINQRSSDANLYRLLDLDPRPTMDGDPDTPKPVSFTVKETVCPRTTQQSPEDCDFKKDGLVKRCMGTVTLNQARGSFDISCDKDNKRFALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | Human | Antiproliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 ± SD : >250μM |
| dbacp02810 | DP1 | KLAKLAKKLAKLAK | Protein transduction domain | Induction of apoptosis | MTT/MTS assay | MCA205 | Renal cancer | LC50 : < 50 µM |
| dbacp02811 | DP1 | KLAKLAKKLAKLAK | KLA sequence repeats, motif-based design | Induction of apoptosis | MTT/MTS assay | MCA205 | Renal cancer | LC50 : < 50 µM |
| dbacp02972 | GA-K3 | FLGWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 41.21 µM |
| dbacp02979 | GA-K3 | FLGWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 41.21 µM |
| dbacp02986 | GA-K4 | FLKWLFKWAKK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 21.48 µM |
| dbacp02993 | GA-K4 | FLKWLFKWAKK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 21.48 µM |
| dbacp03000 | GA-W3 | FLGWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.88 µM |
| dbacp03007 | GA-W3 | FLGWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.88 µM |
| dbacp03014 | GA-W4 | FLWWLFKWAWK | Undecapeptide analogues derived from Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 :22.59 µM |
| dbacp03021 | GA-W4 | FLWWLFKWAWK | Brevinin-1EMa | Cell membrane disruption | MTT/MTS assay | A-498 | Renal cancer | IC50 : 22.59 µM |
| dbacp03033 | Gageostatin A | ELLVDLL | Bacillus subtilis | Perturbation of the cell membrane | Sulforhodamine B (SBR) assay | ACHN | Renal cancer | GI50 : 4.6–19.6 μg/mL |
| dbacp03058 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK293 | Renal cancer | IC50 : 5.62 µg/ml |
| dbacp03059 | GGN6 | FLPLLAGLAANFLPTIICKISYKC | Skin of a Korean frog, wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK301 | Renal cancer | IC50 : 5.75 µg/ml |
| dbacp03387 | Interferon gamma (IFN-gamma) | MNYTSYILAFQLCVILCSSGYYCQAMFFKEIENLKEYFNASNPDVADGGPLFLDILKNWREESDKTIIQSQIVSFYLKLFENFKDNQIIQRSMDTIKEDMLFKFFNSSTSKRSDFLKLIQIPVNDMQVQRKAINELIKVMNDLSPRSNLRKRKRSQNLFRGRRASK | Giant panda | Regulation of immune response | Whole-blood IFN-gamma assay,Real-time reverse transcription–polymerase chain reaction (RT-PCR) assay | HEK293 | Renal cancer | No activity |
| dbacp03408 | Interferon gamma (IFN-gamma) | MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQIISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQLLPESSLRKRKRSRC | Mouse | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 ± SD : > 250μM |
| dbacp04450 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of cancer membrane integrity | Not specified | Not specified | Renal cancer | MIC : 1 – 100 µg/ml |
| dbacp04460 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Renal cancer | MIC : 1 – 100 µg/ml |
| dbacp04469 | Maculatin 1.4 | GLLGLLGSVVSHVLPAITQHL | Fringed Tree Frog, Australia | Disruption of cancer cell membrane integrity | Not specified | Not specified | Renal cancer | IC50 : 10−5 - 10−6 M |
| dbacp04534 | Magainin G | GIGKFLHSAKKFAKAFVAEIMNS | African clawed frog | Dissipate ion gradients; Induce osmotic lysis; Membrane damage | Trypan blue assay | Daudi | Renal cancer | IC50 : 38 µg/ml |
| dbacp05399 | Peptide deformylase, mitochondrial | MARLWGALSLWPLWAAVPWGGAAAVGVRACSSTAAPDGVEGPALRRSYWRHLRRLVLGPPEPPFSHVCQVGDPVLRGVAAPVERAQLGGPELQRLTQRLVQVMRRRRCVGLSAPQLGVPRQVLALELPEALCRECPPRQRALRQMEPFPLRVFVNPSLRVLDSRLVTFPEGCESVAGFLACVPRFQAVQISGLDPNGEQVVWQASGWAARIIQHEMDHLQGCLFIDKMDSRTFTNVYWMKVND | Human | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 ± SD : >250 μM |
| dbacp05653 | Protein farnesyltransferase subunit beta | MASSSSFTYYCPPSSSPVWSEPLYSLRPEHARERLQDDSVETVTSIEQAKVEEKIQEVFSSYKFNHLVPRLVLQREKHFHYLKRGLRQLTDAYECLDASRPWLCYWILHSLELLDEPIPQIVATDVCQFLELCQSPDGGFGGGPGQYPHLAPTYAAVNALCIIGTEEAYNVINREKLLQYLYSLKQPDGSFLMHVGGEVDVRSAYCAASVASLTNIITPDLFEGTAEWIARCQNWEGGIGGVPGMEAHGGYTFCGLAALVILKKERSLNLKSLLQWVTSRQMRFEGGFQGRCNKLVDGCYSFWQAGLLPLLHRALHAQGDPALSMSHWMFHQQALQEYILMCCQCPAGGLLDKPGKSRDFYHTCYCLSGLSIAQHFGSGAMLHDVVMGVPENVLQPTHPVYNIGPDKVIQATTHFLQKPVPGFEECEDAVTSDPATD | Rat | Anti-proliferative effect | Formate dehydrogenase–coupled PDF assay, Thymidine incorporation assay | HEK293 | Renal cancer | IC50 : > 250μM |
| dbacp05709 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK294 | Renal cancer | IC50 : >100 µg/ml |
| dbacp05710 | PTP1 | LLAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK302 | Renal cancer | IC50 : >100 µg/ml |
| dbacp05714 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK295 | Renal cancer | IC50 : >100 µg/ml |
| dbacp05715 | PTP2 | FAGLAANFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK303 | Renal cancer | IC50 : >100 µg/ml |
| dbacp05719 | PTP4 | FLKLLKKLAAKFLPTIICKISYKC | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK296 | Renal cancer | IC50 : 26.15 µg/ml |
| dbacp05724 | PTP5 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK297 | Renal cancer | IC50 : 15.11 µg/ml |
| dbacp05729 | PTP6 | FLKLLKKLAAKLF | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK298 | Renal cancer | IC50 : 14 µg/ml |
| dbacp05734 | PTP7 | FLGALFKALSKLL | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK299 | Renal cancer | IC50 : 6.71 µg/ml |
| dbacp05739 | PTP8 | FLKLLAGLLKNFA | Skin of a Korean frog, Wrinkled frog | Induce apoptosis | MTT/MTS assay | HEK300 | Renal cancer | IC50 : 26.8 µg/ml |
| dbacp05950 | RGD-La | RGDLLRHVVKILEKYL | Arg-Gly-Asp(RGD) tripeptide ana temporins | Cell membrane disintegration | MTT/MTS assay | HEK-293T | Renal cancer | 27.86 Inhibition ratio at 50 µg/ml |
| dbacp05959 | RGD-Las | RGDLLRHVVKILSKYL | Arg-Gly-Asp(RGD) tripeptide ana temporins | Cell membrane disintegration | MTT/MTS assay | HEK-293T | Renal cancer | 32.52 Inhibition ratio at 50 µg/ml |
| dbacp06255 | Temporin-La | LLRHVVKILEKYL | Temporins family | Cell membrane disintegration | MTT/MTS assay | HEK-293T | Renal cancer | 30.82 inhibition ratio at 50 µg/ml |
| dbacp06264 | Temporin-Las | LLRHVVKILSKYL | Temporins family | Cell membrane disintegration | MTT/MTS assay | HEK-293T | Renal cancer | 30.90 inhibition ratio at 50 µg/ml |
| dbacp06612 | Maculatin 1.3 | GLLGLLGSVVSHVVPAIVGHF | Fringed Tree Frog, Australia | Disruption of either cancer or bacterial cell membrane integrity | Not specified | Not specified | Renal cancer | IC50 : 10−5 to 10−6 M |
| dbacp06766 | M1-21 | rrrqrrkkrg-QTQPRLGPPQTPAGGCSILIF | Synthetic | FOXM1 inhibitor | Cell Viability assay | 786-0 | Renal Cancer | IC50 = 13.5 µM |
| dbacp08138 | Laterosporulin10 (LS10) | ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEGGPCQL | Brevibacillus sp. strain SKDU10 | Apoptosis inducing | MTT assay | HEK-293T | Renal Cancer | 20% cytotoxicity 5 μM concentration |
| dbacp08176 | Peptide - 1 | GF(A6c)G(A6c)KK(A6c)G(A6c)F(A6c)G(A6c)GKK(A6c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 = 3.0 µM |
| dbacp08188 | Peptide - 2 | GF(A6c)G(A6c)R(A6c)G(A6c)F(A6c)G(A6c)GR(A6c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 = 5.6 µM |
| dbacp08196 | Peptide - 3 | GF(A6c)G(A6c)Orn(A6c)G(A6c)F(A6c)G(A6c)GOrn(A6c)Orn-Orn- Orn- Orn | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 = 4.7 µM |
| dbacp08204 | Peptide - 4 | GF(A6c)G(A6c)Dab(A6c)G(A6c)F(A6c)G(A6c)GDab(A6c)Dab-Dab-Dab-Dab | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 = 2.1 µM |
| dbacp08212 | Peptide - 6 | GF(A5c)G(A5c)K(A5c)G(A5c)F(A5c)G(A5c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 > 7.5 µM |
| dbacp08220 | Peptide - 7 | GF(A5c)G(A5c)R(A5c)G(A5c)F(A5c)G(A5c)GR(A5c)RRRR | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 > 7.5 µM |
| dbacp08228 | Peptide - 8 | GF(A6c)G(Tic)K(A6c)G(Tic)F(A6c)G(Tic)GK(Tic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 > 7.5 µM |
| dbacp08236 | Peptide - 9 | GF(A6c)G(Oic)K(A6c)G(Oic)F(A6c)G(Oic)GK(Oic)KKKK | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 > 7.5 µM |
| dbacp08244 | Peptide - 10 | GF(A5c)G(A6c)K(A5c)G(A6c)F(A5c)G(A6c)GK(A5c)KKKK | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 > 7.5 µM |
| dbacp08252 | Peptide - 11 | KKKKGF(A6c)G(A6c)K(A6c)G(A6c)F(A6c)G(A6c)GK(A6c) | Synthetic | Not Available | CellTiter-Glo assay | A-498 | Renal Cancer | IC50 = 4.2 µM |
| dbacp08316 | Sample Peptide 1 from US011339203B2 | LTSVVFILICCFHLENIFVLLKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | CAKI-2 | Renal Cancer | Cell Viability = 48% at 25 μM |
| dbacp08317 | Sample Peptide 2 from US011339203B2 | FIGNLALSDLLAGVAYTANLLLKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | CAKI-2 | Renal Cancer | Cell Viability = 0.4% at 25 μM |
| dbacp08322 | Sample Peptide 3 from US011339203B2 | WFLREGSMFVALSASVFSLLAIKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | CAKI-2 | Renal Cancer | Cell Viability = 45.8% at 25 μM |
| dbacp08323 | Sample Peptide 4 from US011339203B2 | FLLISACWVISLILGGLPIMGWKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | CAKI-2 | Renal Cancer | Cell Viability = 85.6% at 25 μM |
| dbacp08324 | Sample Peptide 5 from US011339203B2 | LYHKHYILECTTVFTLLLLSIVILYCRIKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | CAKI-2 | Renal Cancer | Cell Viability = 77.6% at 25 μM |
| dbacp08325 | Sample Peptide 6 from US011339203B2 | VIIVLSVFIACWAPLFILLLLKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | CAKI-2 | Renal Cancer | Cell Viability = 59.7% at 25 μM |
| dbacp08326 | Sample Peptide 7 from US011339203B2 | LFRAEYFLVLAVLNSGTNPIIKKRTLRKNDRKKR | Synthetic | Not Available | CCK-8 assay | CAKI-2 | Renal Cancer | Cell Viability = 66.3% at 25 μM |
| dbacp08342 | VLL-28 | VLLVTLTRLHQRGVIYEKWRHFSGRKYR | Sulfolobus islandicus | Not Available | MTT assay | HEK-293T | Renal Cancer | IC50 = 10 μM |
| dbacp08423 | 5-2C | NYPQRPCRGDKGPDC | Synthetic | Not Available | MTT assay | 293T | Renal Cancer | IC50 = 1.107 μM |